| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AED |
| Uniprot No | Q9UJV3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-735aa |
| 氨基酸序列 | MGESPASVVLNASGGLFSLKMETLESELTCPICLELFEDPLLLPCAHSLCFSCAHRILVSSCSSGESIEPITAFQCPTCRYVISLNHRGLDGLKRNVTLQNIIDRFQKASVSGPNSPSESRRERTYRPTTAMSSERIACQFCEQDPPRDAVKTCITCEVSYCDRCLRATHPNKKPFTSHRLVEPVPDTHLRGITCLDHENEKVNMYCVSDDQLICALCKLVGRHRDHQVASLNDRFEKLKQTLEMNLTNLVKRNSELENQMAKLIQICQQVEVNTAMHEAKLMEECDELVEIIQQRKQMIAVKIKETKVMKLRKLAQQVANCRQCLERSTVLINQAEHILKENDQARFLQSAKNIAERVAMATASSQVLIPDINFNDAFENFALDFSREKKLLEGLDYLTAPNPPSIREELCTASHDTITVHWISDDEFSISSYELQYTIFTGQANFISKSWCSWGLWPEIRKCKEAVSCSRLAGAPRGLYNSVDSWMIVPNIKQNHYTVHGLQSGTRYIFIVKAINQAGSRNSEPTRLKTNSQPFKLDPKMTHKKLKISNDGLQMEKDESSLKKSHTPERFSGTGCYGAAGNIFIDSGCHYWEVVMGSSTWYAIGIAYKSAPKNEWIGKNASSWVFSRCNSNFVVRHNNKEMLVDVPPHLKRLGVLLDYDNNMLSFYDPANSLHLHTFDVTFILPVCPTFTIWNKSLMILSGLPAPDFIDYPERQECNCRPQESPYVSGMKTCH |
| 预测分子量 | 83,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于“AED重组蛋白”的示例参考文献(注：AED重组蛋白的具体定义需结合领域背景，以下内容为假设性示例)：
---
1. **文献名称**：*Optimized Expression of AED Recombinant Protein in Insect Cells*
**作者**：Chen L, et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统高效表达AED重组蛋白，通过密码子优化和温度调控提升蛋白产量，并验证其生物活性可用于体外酶动力学研究。
2. **文献名称**：*AED Recombinant Protein as a Novel Therapeutic Target in Cancer*
**作者**：Kim S, et al.
**摘要**：探讨AED重组蛋白通过抑制肿瘤细胞增殖通路(如PI3K/AKT)发挥抗肿瘤作用，动物实验显示其显著降低小鼠模型中肿瘤体积。
3. **文献名称**：*Structural and Functional Analysis of AED Protein via Recombinant Expression*
**作者**：Müller T, et al.
**摘要**：通过大肠杆菌重组表达系统获得AED蛋白，结合X射线晶体学解析其三维结构，揭示其底物结合域的关键氨基酸残基。
4. **文献名称**：*AED Recombinant Protein Vaccine for Viral Immunity*
**作者**：Garcia R, et al.
**摘要**：开发基于AED重组蛋白的亚单位疫苗，实验证明其可诱导小鼠产生中和抗体，为抗病毒免疫策略提供新思路。
---
**说明**：
- 以上文献为示例，实际研究中需根据具体蛋白名称(如AED的全称)检索真实文献。
- 若AED指特定领域术语(如抗癫痫蛋白、酶类等)，建议补充全称或研究背景以获取更精准的参考文献。
**Background of AED Recombinant Protein**
Recombinant proteins, engineered through genetic modification, are pivotal in modern biotechnology and medicine. AED recombinant protein, a synthetic biomolecule, is typically produced by inserting a target gene (AED) into a host system (e.g., *E. coli*, yeast, or mammalian cells*) to express the desired protein. The "AED" designation may refer to a specific functional domain, therapeutic target, or proprietary name linked to its application, such as in immunotherapy, enzymatic activity, or cellular signaling.
The development of AED leverages recombinant DNA technology, enabling precise control over protein structure, post-translational modifications, and scalability. This ensures high purity and consistency, critical for research, diagnostics, and therapeutic uses. For instance, AED may be designed to mimic natural proteins involved in immune regulation or disease pathways, enhancing its utility in drug development or biomarker studies.
Applications of AED recombinant protein span multiple fields. In therapeutics, it might serve as a biologic drug for treating cancers, autoimmune disorders, or infectious diseases by targeting specific receptors or pathogens. In research, it acts as a tool to study protein interactions, cellular mechanisms, or as a standard in assays. Its production often adheres to Good Manufacturing Practice (GMP) standards, ensuring safety for clinical trials.
Challenges include optimizing expression systems to balance yield and functionality, minimizing immunogenicity, and ensuring stability. Advances in protein engineering, such as fusion tags or PEGylation, further enhance AED’s efficacy and half-life.
Overall, AED recombinant protein exemplifies the convergence of genetic engineering and translational medicine, offering tailored solutions for unmet medical needs while driving innovation in biopharmaceuticals.
×
